Navigation Links
HGS announces positive Phase 2 LymphoStat-B at ACR meeting
Date:11/9/2007

ROCKVILLE, Maryland November 9, 2007 Human Genome Sciences, Inc. (Nasdaq: HGSI) today announced the presentation of Phase 2 clinical results demonstrating that LymphoStat-B (belimumab) achieved a sustained improvement in disease activity across multiple clinical measures, decreased the frequency of disease flares over time, and was well tolerated through 2.5 years on treatment in combination with standard of care in patients with active systemic lupus erythematosus (SLE). The results will be the subject of an oral presentation today in Boston at the Annual Scientific Meeting of the American College of Rheumatology (ACR).

SLE is a chronic disease, and patients need new therapies that provide durable efficacy with a favorable safety profile, said Michelle A. Petri, M.D., M.P.H., Professor, Division of Rheumatology, Department of Medicine, Johns Hopkins University. The Phase 2 results presented at ACR showed that the significant clinical benefit observed for LymphoStat-B in serologically active SLE patients at 52 weeks appears to be sustained through 2.5 years. We look forward to further evaluation of LymphoStat-B in larger Phase 3 studies, which are ongoing.

A separate poster presentation of the safety profile of LymphoStat-B showed that LymphoStat-B was well tolerated in combination with SLE standard-of-care therapy during long-term exposure, with incidence rates of adverse events, serious adverse events, malignancies, infections and laboratory abnormalities remaining comparable to placebo or decreasing through 2.5 years of treatment (Merrill et al).

The results through 2.5 years confirm and extend the results reported at Weeks 52 and 76, said David C. Stump, M.D., Executive Vice President, Research and Development, HGS. At Week 52 in LymphoStat-B patients with active SLE, we saw significant reductions in SLE disease activity versus placebo as measured by the SELENA SLEDAI and BILAG indices, the Physicians Global Assessment,
'/>"/>

Contact: Jerry Parrot
Jerry_Parrott@hgsi.com
301-315-2777
Edelman Public Relations
Source:Eurekalert

Page: 1 2 3 4

Related biology news :

1. Selexis Announces Advanced Approach to Maximize Power of Genetic Elements for Rapid Development of High Performance Cell Lines
2. LaserCard Corporation Announces Expansion of Middle East Project
3. BIO-key(R) Announces Contracts for New Criminal Justice Data Sharing Solution
4. Balzan Foundation announces 2007 winners
5. The American Society of Plant Biologists announces 2007 awards
6. ASPB announces Summer Undergraduate Research Fellowship 2007 recipients
7. NIST announces 56 new awards for innovative technology research and development
8. Titanium Group Announces Contract With Haitong Securities
9. Measurement Specialties, Inc. Announces Impact of German Business Tax Reform 2008 Resulting in Lower Combined German Tax Rate - Impacts 2Q08 Reported Financial Results
10. FIJI Water announces sustainable growth initiative with commitment to help mitigate climate change
11. Positive results for airway bypass
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/10/2015)... April 10, 2015 Research and ... the "Security Competitive Profiles - NEC" report ... NEC will continue to supply a range ... market, with a company focus on the development of ... Winning opportunities in the Asia-Pacific ...
(Date:4/8/2015)... , April 8, 2015  Infinisource, a ... and services, and Morpho, a leading supplier of ... to produce the market,s most advanced biometrically-enabled time ... iSolved NXG time clock is setting a bold, ... labor data for the small and mid-size employer. ...
(Date:4/2/2015)... , April 2, 2015 ... DERMALOG by far outperforms the strongest competitors, showing ... high accuracy, the system is capable of a ... speed proves up to be ten times faster ... its runner-up performance.      (Photo: ...
Breaking Biology News(10 mins):NEC Security Competitive Profile 2015 2iSolved Time Clock Offers Unmatched Accuracy due to Morpho Biometrics 2iSolved Time Clock Offers Unmatched Accuracy due to Morpho Biometrics 3DERMALOG AFIS Emerges as Performance Winner in NIST Benchmark Test 2DERMALOG AFIS Emerges as Performance Winner in NIST Benchmark Test 3
... has already had dramatic effects on individual species, with ... migration. But, in a new study from the open-access ... Getz show that the impact of climate change on ... by a top predator - the reintroduced gray wolf ...
... A newly discovered mechanism by which an infectious fungus ... virulence, according to Howard Hughes Medical Institute investigators at ... in light following fungal invasion of the human body ... sparks infection, the researchers said. , The discovery in ...
... damage to the heart that can cause congestive ... limited ability of the myocardium to regenerate and ... now document the existence of a previously unrecognized ... therapeutic potency for myocardial tissue regeneration following myocardial ...
Cached Biology News:Gray wolves maintain the food chain in winter 2Light therapy may combat fungal infections, new evidence suggests 2Light therapy may combat fungal infections, new evidence suggests 3
(Date:4/17/2015)... (PRWEB) April 17, 2015 Global ... the GTCbio Stem Cell Summit 2015 April 27 - ... the latest developments in all areas of stem cell ... of stem cells and regenerative medicine. , The ... trials, as well as translational research in stem cell ...
(Date:4/16/2015)... and OSAKA, Japan , ... Research Application (CiRA) of Kyoto University and Takeda ... will work together to develop clinical applications of ... heart failure, diabetes mellitus, neurological disorders and cancer ... Applications" (T-CiRA) is designed to expedite multiple research ...
(Date:4/16/2015)... CA (PRWEB) April 16, 2015 ... the Buzz of BIO Contest for the ... Organization (BIO), the 2015 BIO International Convention will take ... Philadelphia, Pennsylvania. During the Buzz of BIO contest, industry ... to see present at the conference. The community voting ...
(Date:4/16/2015)... CHARLOTTE, N.C. (PRWEB) April 16, 2015 ... North Carolina at Charlotte (UNC Charlotte) spin-out company, ... David L. Cooper, Ph.D., M.D., as Chief Operating ... 20 years of experience in developing clinical diagnostic ... oncology and infectious disease. , Cooper’s extensive career ...
Breaking Biology Technology:Global Stem Cells Group To Join GTCbio Stem Cell and Regenerative Medicine Summit in Boston, April 27-29, 2015 2Global Stem Cells Group To Join GTCbio Stem Cell and Regenerative Medicine Summit in Boston, April 27-29, 2015 3CiRA and Takeda Enter 10-year Collaboration on iPS Cell Research 2CiRA and Takeda Enter 10-year Collaboration on iPS Cell Research 3Proove Bisociences to Participate in the Buzz of BIO at the 2015 BIO International Convention 2Proove Bisociences to Participate in the Buzz of BIO at the 2015 BIO International Convention 3OncoTAb Names Dr. David L. Cooper as COO 2
... May 13 /Xinhua-PRNewswire/ -- Chindex International,Inc. (Nasdaq: CHDX ... and products in the People,s Republic of China,announced that ... and Exchange Commission (SEC) that, if declared effective by ... to time, up to $100 million,of its common stock ...
... /Xinhua-PRNewswire/ -- Chindex International,Inc. (Nasdaq: CHDX ) a ... in the People,s Republic of China,announced that it intends ... March 31, 2008, on Thursday, June 12, 2008., ... Thursday, June,12, 2008 at 9:00 a.m. Eastern Time to ...
... Patients Shipped in the Quarter ... ... BEDFORD, Mass., May 13 Insulet Corporation,(Nasdaq: PODD ), a ... today announced financial results for,the first quarter ended March 31, 2008., ...
Cached Biology Technology:Chindex International Announces Shelf Registration, Related Strategy and Guidance 2Chindex International Announces Shelf Registration, Related Strategy and Guidance 3Chindex International Announces Shelf Registration, Related Strategy and Guidance 4Chindex International Announces Shelf Registration, Related Strategy and Guidance 5Chindex International Announces Conference Call to Discuss Its Fiscal 2008 Fourth Quarter and Year End Results on Thursday, June 12, 2008 2Chindex International Announces Conference Call to Discuss Its Fiscal 2008 Fourth Quarter and Year End Results on Thursday, June 12, 2008 3Insulet Reports First Quarter 2008 Results 2Insulet Reports First Quarter 2008 Results 3Insulet Reports First Quarter 2008 Results 4Insulet Reports First Quarter 2008 Results 5Insulet Reports First Quarter 2008 Results 6Insulet Reports First Quarter 2008 Results 7
Request Info...
Goat polyclonal to MLH3 Immunogen: Synthetic peptide: RQSLQQSMPPCEPP (Human) from C Terminus of the protein sequence according to NP_055196....
IRF7 Immunogen: Synthetic peptide corresponding to residues E(463) G T Q R E G V S S L D S S S(477) of human IRF7. Storage: -20 C, Avoid Freeze/Thaw Cycles...
Rabbit polyclonal to NMDAR1 e/f/g/h ( Abpromise for all tested applications)....
Biology Products: